Mogelijk gemaakt door 
Translate
Translate
30 April 2025
Cizzle Biotechnology Holdings plc
("Cizzle", "Cizzle Biotechnology", or the "Company")
Final results for the year ended 31 December 2024
Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, announces the publication of the Company's Annual Report and Financial Statements for the year ended 31 December 2024 ("Annual Report").
The Annual Report is available via http://www.rns-pdf.londonstockexchange.com/rns/8506G_1-2025-4-30.pdf and will shortly be available to view on the on the National Storage Mechanism (NSM) and the Company's website: https://cizzlebiotechnology.com
Enquiries:
|
Cizzle Biotechnology Holdings plc |
Via IFC Advisory |
|
Allan Syms (Executive Chairman) |
|
|
Allenby Capital Limited |
+44(0) 20 3328 5656 |
|
John Depasquale / Piers Shimwell (Corporate Finance) |
|
|
Stefano Aquilino / Amrit Nahal (Sales and Corporate Broking) |
|
|
IFC Advisory Limited |
+44(0) 20 3934 6630 |
|
|
Tim Metcalfe |
|
|
|
Florence Staton |
|
|
About Cizzle Biotechnology
Based on the pioneering work of Professor Coverley and colleagues, on a naturally occurring variant of the cell nuclear protein CIZ1, the CIZ1B biomarker is highly associated with the presence of early-stage cancer. The company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the early detection of lung cancer and has now entered into commercial royalty-bearing arrangements to license its proprietary technology, and into collaborations with centres of excellence in cancer care. Cizzle was admitted to the Standard segment of the main market of the London Stock Exchange in May 2021.
For more information, please see https://cizzlebiotechnology.com
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.
